Premium
Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
Author(s) -
Farooqi Nasr,
Gran Bruno,
Constantinescu Cris S.
Publication year - 2010
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2010.06982.x
Subject(s) - multiple sclerosis , experimental autoimmune encephalomyelitis , medicine , encephalomyelitis , disease , neuroscience , autoimmune disease , immunology , intensive care medicine , pathology , psychology
J. Neurochem. (2010) 115 , 829–844. Abstract The precise aetio‐pathology of multiple sclerosis remains elusive. However, important recent advances have been made and several therapies have been licensed for clinical use. Many of these were developed, validated or tested in the animal model, experimental autoimmune encephalomyelitis (EAE). This systematic review aims to assess whether the current disease modifying treatments and those that are the closest to the clinic are justified on the basis of the results of EAE studies. We discuss some aspects of the utility and caveats of EAE as a model for multiple sclerosis drug development.